As with bevacizumab and sorafenib, resistance to anti-VEGF therapy with ramucirumab is often thought to result from an escape mechanism of the angiogenic process through the activation of pathways other than the VEGF pathway [233], although the evidence according to the mechanisms of resistance acquisition for ramucirumab in HCC and other cancer types is limited. This evidence concerns the gene VEGFA and cancer.